Navigation Links
ULURU Inc. Reports Third Quarter 2010 Financial Results
Date:11/15/2010

lizing plans for our 0.75 gram line extension;
  • Successfully completing 150 audits, essential to maintaining our CE Mark approval;
  • Expanding and advancing discussions on numerous strategic partnering opportunities;
  • Planning for the launch of multiple products in international markets in early 2011; and
  • Upgrading our independent sales force and substantially expanding the number of representatives.

  • We believe that the recent progress that has been made will begin to favorably impact our financial results in the fourth quarter, with the major impact being experienced in 2011."

    Operating ResultsRevenues

    Revenue for the third quarter of 2010 was $62,000, compared to $130,000 for the third quarter of 2009.  The decrease of $68,000 in revenue was due primarily to a decrease of $25,000 in OraDisc™ licensing fees due to an adjustment in revenue amortization and the impact of the divestiture of Zindaclin® technologies in June 2010, which resulted in decreases of $2,000 in licensing and $39,000 in royalties.

    Research and Development

    Research and development expenses for the third quarter of 2010 were $296,000, including $32,000 in share-based compensation, compared to $376,000, including $31,000 in share-based compensation, for the third quarter of 2009.  The decrease of $80,000 in research and development expenses consisted of decreases in scientific personnel costs of $34,000, regulatory consulting expenses of $11,000, direct research costs of $8,000, and clinical testing expenses for our wound care technologies of $29,000.  

    Selling, General and Administrative

    Selling, general and administrative expenses for the third quarter of 2010 were $666,000, including $26,000 in share-based compensation, compared to $981,000, including $126,000 in share-based compensation, for the third quarter of 2009.  The decrease of approximately $315,000 in
    '/>"/>

    SOURCE ULURU Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
    2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
    3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
    4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
    5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
    6. ULURU Inc. Reports Second Quarter 2010 Financial Results
    7. ULURU Inc. Announces Conference Call
    8. ULURU Inc. Provides Altrazeal® Clinical Update
    9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    10. Spherix Reports Second Quarter Earnings
    11. Tapestry Reports Second Quarter 2007 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... Scott Steiger lives in St. Louis ... the past 20 years, he,s traveled extensively and prior to that, ... six of the seven continents. Travel is a big part of ... - http://photos.prnewswire.com/prnh/20141126/161077 So when he designs ... of what,s required. His latest creation is the Road ...
    (Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
    (Date:11/26/2014)... The medical magnetic resonance imaging (MRI) ... with world market revenues for 2013 at $5.1 ... types of medical imaging have led to improvements ... conditions in children and adults, each imaging procedure ... Medical Imaging Markets , analyzes the current and ...
    Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
    ... - New Data from Phase III Intergroupe Francophone ... Mass., July 02, 2007 /PRNewswire-FirstCall/ --,Millennium Pharmaceuticals, Inc. ... comparative Phase III clinical trial evaluating a,VELCADE based ... induction therapy prior to stem cell transplantation,(SCT), the ...
    ... 2 July, 2007 -- Ablynx today announced ... study of its lead,development programme, ALX-0081, an ... targeting von Willebrand Factor (vWF), which can,reduce ... acute coronary,syndrome. , The Phase I study ...
    Cached Medicine Technology:Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 2Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 3Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 5Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 6Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2
    (Date:11/27/2014)... (PRWEB) November 28, 2014 Recently, iFitDress.com, ... added 100 new items to its assortment of ... big discounts, up to 70% off. Some models are ... beautiful discounted black cocktail dresses can enjoy a low ... always have something special for its clients. The business ...
    (Date:11/27/2014)... 2014 Today, Digital-Signage-China.com adds 2 new items ... a digital signage media player promotion for Dec. 2014. ... a shopping wave in April, and this promotion will help ... find her desired models on our website, she/he can contact ... , The new models come in the latest designs, and ...
    (Date:11/27/2014)... 28, 2014 This is a professional ... global Bronchoscopes industry with a focus on the Chinese ... status of the Bronchoscopes manufacturers and is a valuable ... interested in the industry. , Firstly, the report provides ... applications and manufacturing technology. Then, the report explores the ...
    (Date:11/27/2014)... 28, 2014 Cyber Monday cannot come ... & Caicos. This boutique resort, ranked #1 out ... a few highly sought out openings before Christmas on ... are offering every seventh night complimentary if booked directly ... having a January 2015 promotion where every fourth night ...
    (Date:11/27/2014)... St. Petersburg, Fl (PRWEB) November 28, 2014 ... , Beautiful Christmas boxes with bows on top, filled ... All prices are deeply discounted today while quantities last ... here . , All products are also available on Amazon ... are found on each Sublime shop product page for ease. ...
    Breaking Medicine News(10 mins):Health News:Beautiful Black Cocktail Dresses Offered by Top Dress Supplier iFitDress.com 2Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:Big Christmas Sales Begin Today at Sublime Beauty® for all Christmas Gift Selections and Skincare Sets 2
    ... A gene which is connected to Parkinson’s disease can ... revealed by the University of Colorado researchers, which has ... ,The results suggest the possibility for new drugs that ... further cell damage. Parkinson’s disease is a disorder that ...
    ... The secret of straight and curly hair lies four millimeters ... also trying to find the reason for the whitening of ... hair and straight, for straight hair. ,To get ... by Bruno Bernard, head of hair biology at L'Oreal, grew ...
    ... progress of twin babies, premature by 15 weeks through the ... 2 pounds at birth. // The Internet was chosen as ... and family informed with regard to the progress of the ... charity drive is also on to get additional funds for ...
    ... There appears to be a molecular link between the ... contains a high level of fat. // This is ... due to the high-fat diet, according to a recent ... gene encoding the enzyme GnT-4a glycosyltransferase (GnT-4a) disrupts insulin ...
    ... therapy research can be carried out in terminally ill ... are more than the risk involved in these patients, ... first cloned dolly sheep. Professor Wilmut is appointed as ... Edinburgh University. ,Professor Wilmut feels that stem ...
    ... done by Stephen Thom, MD, Ph.D., Professor of Emergency Medicine ... ,He said that a course of hyperbaric oxygen treatments ... body of the patient. ,Stem cells are progenitor ... the ability to differentiate into any type of cell. ...
    Cached Medicine News:Health News:Gene Can Keep Brain Cells Alive 2
    The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE® ESR...
    Inquire...
    VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
    Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
    Medicine Products: